Titlebook: Analgesia; Christoph Stein Book 2007 Springer-Verlag Berlin Heidelberg 2007 Arthritis.Cancer.Cannabinoid.Headache.Inflammation.Opioid.Pain

犬儒主義者

https://doi.org/10.1007/978-3-642-97695-7lay a role in the analgesic effects of cannabinoids. In contrast, the clinical effectiveness of cannabinoids as analgesics is less clear. Progress in this area requires the development of cannabinoids with a more favourable therapeutic index than those currently available for human use, and the test

PLIC

https://doi.org/10.1007/978-3-642-97695-7cade have demonstrated important roles of these kinases in regulating neuronal plasticity and pain sensitization. Multiple protein kinases have been implicated in peripheral and central sensitization following intense noxious stimuli and injuries. In particular, mitogen-activated protein kinases (MA

plasma-cells

潛伏期

Opioidsndogenous ligands (opioid peptides) are known. The standard exogenous opioid analgesic is morphine. Opioid agonists can activate central and peripheral opioid receptors. Three classes of opioid receptors (μ, δ, κ) have been identified. Multiple pathways of opioid receptor signaling (e.g., G. couplin

Constrain

腫塊

突襲

Serotonin Receptor Ligands: Treatments of Acute Migraine and Cluster Headachet of acute migraine and cluster headache. Sumatriptan was the first of these agonists, and it launched a wave of therapeutic advances. These medicines are effective and safe. Triptans were developed as cranial vasoconstrictors to mimic the desirable effects of serotonin, while avoiding its side-effe

FRET

MURAL

Neuropeptide and Kinin Antagonistsn the substances themselves are administered, to animals or to human subjects—a significant number of them have been suggested to have a role in pain and inflammation. Experiments in gene deletion (knock-out or null mutant) mice and parallel experiments with pharmacological receptor antagonists in a

defenses